Hemophilia A - Pipeline Review, H1 2018: Crucial Insights Compiled in a New Business Study for Healthcare

Published on : Jun 13, 2018

Albany, New York, June 13, 2018: Hemophilia, a critical medical condition, characterized by spontaneous hemorrhage, easy bruising, and poor clotting, triggered by deficient FVIII. Pharmaceutical companies and research institutes are carrying out judicious research in drug innovation pertaining to FVIII. To understand current developments in hemophilia A therapeutics, Market Research Hub (MRH) has added a new study titled, ‘Hemophilia A - Pipeline Review, H1 2018’, to its repository.  

Gene Therapy Likely to Emerge as Potential Treatment for Hemophilia A Therapeutics

Attributed to heredity and spontaneous mutation, Hemophilia A is caused by scarce functional clotting factor (FVIII). Biopharmaceutical companies are investing extensively to propel novel innovations in hemophilia A therapeutics development. Several drugs are at various stages of clinical research and are soon expected to be commercialized to offer medical relief to end-users afflicted with hemophilia A. Companies are diverting investments towards gene therapy for hemophilia A therapeutics.  

In a recent development, Bayer, a leading biopharmaceutical company has partnered with Ultragenyx in its strife to attain potent gene therapies targeting hemophilia A therapeutics development. Further, Bayerhas recently applied for Biologics Licence Application (BLA) for BAY94-9027 which essentially is a recombinant human Factor VIII aimed to treat hemophilia A effectively. The drug exhibited favorable results in phase 3 of PROTECT VIII trial. The company claims that the drug treats hemophilia A patients aptly with few infusions.

Alongside, Alnylam Pharmaceuticals Inc, a veteran in RNA-based therapies has entered into a joint initiative with Sanofi Genzyme. The latter will gain absolute rights to develop and commercialize fitusiran, a probable drug for hemophilia A, presently at a development stage. According to the agreement, Sanofi is entrusted to carry out commercialization of the drug across the globe, while Alnylam will be procuring royalties post sale. This is a breakthrough in hemophilia A therapeutics development and is expected to trigger ample success rates in hemophilia A treatment.

Comprehensive research findings compiled in the report presents veritable insights on various policies and marketing tactics administered by market leaders to ensure growth in hemophilia A therapeutics development market. This section of the report also highlights the core segments present in hemophilia A therapeutics development market. According to the report, the key segments consist of therapeutics development and therapeutics assessment. Based on therapeutics development, the hemophilia A therapeutics development market is stratified as stage of development by companies and stage of development by institutions. Based on therapeutics assessment, the hemophilia A therapeutics development market is split as mechanism of action, route of administration, and molecule type. On the basis of insights highlighted, readers can gauge the implications of these segments on the growth of hemophilia A therapeutics development market. Additionally, readers can also identify the segment that is accounted for maximum revenue generation. Based on these pertinent information, readers can deliver a well-informed marketing strategy that promises maximum revenues in hemophilia A therapeutics development market.  

Key Players in Hemophilia A Therapeutics Development Market

An in-depth summary of research outputs encapsulated in the report portrays core insights on the strategies implemented by market leaders to achieve growth in hemophilia A therapeutics development market. New entrants as well as existing market players can carry out detailed analysis of these strategies and implement profit driven marketing plans to retain their position in hemophilia A therapeutics development market. Leading players identified in hemophilia A therapeutics development market include, Alnylam Pharmaceuticals Inc, Bayer AG, Chugai Pharmaceutical Co Ltd, DBV Technologies SA, Innovare R & D SA De CV, Novo Nordisk AS among others. 

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1821768

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top